THERAPEUTIC POTENTIAL OF THE DUAL EGFR/HER2 INHIBITOR AZD8931 IN CIRCUMVENTING ENDOCRINE RESISTANCE

Ítems similars

• Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors
  per: Barlaam, Bernard, et al.
  Publicat: (2013)
• The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
  per: Nardone, Agostina, et al.
  Publicat: (2018)
• Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
  per: CRAFTER, CLAIRE, et al.
  Publicat: (2015)
• AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
  per: Mu, Zhaomei, et al.
  Publicat: (2014)
• Upregulation of Mucin4 in ER-positive/HER2-Overexpressing Breast Cancer Xenografts with Acquired Resistance to Endocrine and HER2-Targeted Therapies
  per: Chen, Albert C., et al.
  Publicat: (2012)